New Solid Forms: Structural, Supramolecular, and Dehydration-Induced Phase Transitions of Three Hydrated 17α-Alkylated Testosterone Derivatives
Abstract
1. Introduction
2. Materials and Methods
2.1. Crystallization and Crystal Growth
- (i)
- The fluoxymesterone hydrate form (denoted Flu·H2O) was crystallized by slow evaporation from a water–butanol mixture (1:1, v/v) heated at 60 °C and slowly cooled (Figure 1b);
- (ii)
- The oxandrolone hemihydrate form (denoted Oxa·0.5H2O) was crystallized by dissolving anhydrous oxandrolone in ethanol at 60 °C, followed by mixing with distilled water preheated to 60 °C and allowing the solution to cool slowly over several days (Figure 1c);
- (iii)
- The methandienone hemihydrate form (denoted Dbl·0.5H2O) was crystallized by recrystallization from an ethanol and water mixture (1:1, v/v), which was heated as well at 60 °C (Figure 1d).
2.2. Powder X-Ray Diffraction Characterization
2.3. Single-Crystal X-Ray Diffraction Measurements and Structure Refinement
2.4. Theoretical Analysis of Molecular Interactions and Lattice Stability
2.5. Differential Thermal Analysis (DTA) and Thermogravimetric Analysis (TGA) and Stability
3. Results
3.1. Structural Characterization of the Crystals
3.1.1. Dbl·0.5H2O
3.1.2. Oxa·0.5H2O
3.1.3. Flu·H2O
3.2. X-Ray Powder Diffraction Analysis
3.3. Evaluation of Crystalline Form Stability in the Climatic Chamber
- (i)
- Oxa hydrate showed only trace amounts of the initial hydrate after 24 h, which completely disappeared after two weeks.
- (ii)
- Flu hydrate exhibited a less pronounced transformation within the first 24 h but continued to convert over 12 weeks, with a considerable amount of hydrate still present at the end of this period.
- (iii)
- Dbl hydrate experienced a complete phase transformation within 24 h and remained anhydrous throughout the 12-week study.
3.4. Lattice Energies Evaluation
3.5. Computation of Intermolecular Interaction Energies
3.6. DTA/TGA Analysis
4. Conclusions
Supplementary Materials
Author Contributions
Funding
Data Availability Statement
Conflicts of Interest
References
- Griesser, U.J. The Importance of Solvates in the Pharmaceutical Industry. In Polymorphism in the Pharmaceutical Industry; Hilfiker, R., von Raumer, M., Eds.; Wiley-VCH: Weinheim, Germany, 2006; pp. 211–233. [Google Scholar]
- Brittain, H.G. Polymorphism in Pharmaceutical Solids, 2nd ed.; Drugs and the Pharmaceutical Sciences; Informa Healthcare: New York, NY, USA, 2009. [Google Scholar]
- Aitipamula, S.; Banerjee, R.; Bansal, A.K.; Biradha, K.; Desiraju, G.R.; Dikundwar, A.G.; Dubey, R.; Duggirala, N.; Ghogale, P.P.; Ghosh, S.; et al. Polymorphs, Salts, and Cocrystals: What’s in a Name? Cryst. Growth Des. 2012, 12, 2147–2152. [Google Scholar] [CrossRef]
- Alemany, M. The Roles of Androgens in Humans: Biology, Metabolic Regulation and Health. Int. J. Mol. Sci. 2022, 23, 11952. [Google Scholar] [CrossRef] [PubMed]
- Dotson, J.L.; Brown, R.T. The History of the Development of Anabolic-Androgenic Steroids. Pediatr. Clin. N. Am. 2007, 54, 761–769. [Google Scholar] [CrossRef] [PubMed]
- McCullough, D.; Webb, R.; Enright, K.J.; Lane, K.E.; McVeigh, J.; Stewart, C.E.; Davies, I.G. How the love of muscle can break a heart: Impact of anabolic androgenic steroids on skeletal muscle hypertrophy, metabolic and cardiovascular health. Rev. Endocr. Metab. Disord. 2020, 22, 389–405. [Google Scholar] [CrossRef]
- Hervel, G.R.; Knibbs, A.V.; Burkinshaw, L.; Morgan, D.B.; Jones, P.R.; Chettle, D.R.; Vartsky, D. Effects of methandienone on the performance and body composition of men undergoing athletic training. Clin. Sci. 1981, 60, 457–461. [Google Scholar] [CrossRef]
- Woerdeman, J.; Ronde, W. Therapeutic effects of anabolic androgenic steroids on chronic diseases associated with muscle wasting. Expert Opin. Investig. Drugs 2011, 20, 87–97. [Google Scholar] [CrossRef]
- Marchetti, N. Anabolic Medications for Muscle Wasting in Chronic Obstructive Pulmonary Disease. Is the Evidence Getting Stronger? Am. J. Respir. Crit. Care Med. 2019, 199, 87–97. [Google Scholar] [CrossRef]
- Bandeira, L.; Lewiecki, E.M. Anabolic therapy for osteoporosis: Update on efficacy and safety. Arch. Endocrinol. Metab. 2022, 66, 707–716. [Google Scholar] [CrossRef]
- Li, H.; Guo, Y.; Yang, Z.; Roy, M.; Guo, Q. The efficacy and safety of oxandrolone treatment for patients with severe burns: Asystematic review and metaanalysis. Burns 2015, 42, 717–727. [Google Scholar] [CrossRef]
- Przkora, R.; Herndon, D.N.; Suman, O.E. The Effects of Oxandrolone and Exercise on Muscle Mass and Function in Children with Severe Burns. Pediatrics 2007, 119, 109–116. [Google Scholar] [CrossRef]
- Young, G.A.; Yule, A.G.; Hill, G.L. Effects of an anabolic steroid on plasma amino acids, proteins, and body composition in patients receiving intravenous hyperalimentation. J. Parenter. Enter. Nutr. 1983, 7, 221–225. [Google Scholar] [CrossRef] [PubMed]
- Orr, R.; Fiatarone Singh, M. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: Review of efficacy and safety. Drugs 2004, 64, 725–750. [Google Scholar] [CrossRef] [PubMed]
- Bross, R.; Javanbakht, M.; Bhasin, S. Anabolic Interventions for Aging-Associated Sarcopenia. J. Clin. Endocrinol. Metab. 1999, 84, 3420–3430. [Google Scholar] [CrossRef] [PubMed]
- Schroeder, E.T.; Zheng, L.; Yarasheski, K.E.; Qian, D.; Stewart, Y.; Flores, C.; Martinez, C.; Terk, M.; Sattler, F.R. Treatment with oxandrolone and the durability of effects in older men. J. Appl. Physiol. 2004, 96, 1055–1062. [Google Scholar] [CrossRef]
- Dalmau, E.; Armengol-Alonso, A.; Muñoz, M.; Seguí-Palmer, M.Á. Current status of hormone therapy in patients whith hormone receptor positive (HR+) advanced breast cancer. Breast 2014, 23, 710–720. [Google Scholar] [CrossRef]
- Kennedy, B.J. Fluoxymesterone Therapy in Advanced Breast Cancer. N. Engl. J. Med. 1958, 259, 673–675. [Google Scholar] [CrossRef]
- Manni, A.; Arafah, B.M.; Pearson, O.H. Androgen-induced remissions after antiestrogen and hypophysectomy in stage IV breast cancer. Cancer 1981, 48, 2507–2509. [Google Scholar] [CrossRef]
- Stanhope, R.; Bommen, M.; Brook, C.G.D. Constitutional Delay of Growth and Puberty in Boys: The Effect of a Short Course of Treatment with Fluoxymesterone. Acta Pediatr. 1985, 74, 390–393. [Google Scholar] [CrossRef]
- Faqueto, H.; Santos, M.R.; Manfredi, L.H. Anabolic-Androgenic Steroids and Exercise Training: Breaking the Myths and Dealing with Better Outcome in Sarcopenia. Front. Physiol. 2022, 13, 838526. [Google Scholar] [CrossRef]
- Kicman, A.T. Pharmacology of anabolic steroids. Br. J. Pharmacol. 2008, 154, 502–521. [Google Scholar] [CrossRef]
- Solimini, R.; Rotolo, M.C.; Mastrobattista, L.; Mortali, C.; Minutillo, A.; Pichini, S.; Pacifici, R.; Palmi, I. Hepatotoxicity associated with illicit use of anabolic androgenic steroids in doping. Eur. Rev. Med. Pharmacol. Sci. 2017, 21, 7–16. [Google Scholar] [PubMed]
- Anthony, A.; Jaskolski, M.; Nangia, A. Crystal chemistry of some synthetic 2-oxa-steroids: Conformation, packing motifs and isostructurality. Acta Crystallogr. B 2000, 56, 512–525. [Google Scholar] [CrossRef] [PubMed]
- Ginotra, S.K.; Chhikara, B.S.; Singh, M.; Chandra, R. Efficient oxidizing methods for the synthesis of oxandrolone intermediates. Chem. Pharm. Bull. 2004, 52, 989–991. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Karpinska, J.; Erxleben, A.; McArdle, P. 17β-Hydroxy-17α-methylandrosta-1,4-dien-3-one. Acta Crystallogr. E 2013, 60, 69. [Google Scholar] [CrossRef]
- Rendle, D.F.; Trotter, J. Crystal and molecular structure of 17β-hydroxy-17α-methyl-2-oxa-5α-androstan-3-one. J. Chem. Soc. Perkin Trans. 1975, 2, 1361–1365. [Google Scholar] [CrossRef]
- Duax, W.L.; Strong, P.D.; Wolff, M.E. 9a-FLUORO-11S,17S-DIHYDROXY-17a-METHYL-4-ANDROSTEN-3-ONE. Cryst. Struct. Commun. 1979, 8, 985. [Google Scholar]
- Rigaku. CrysAlis PRO; Rigaku Oxford Diffraction: Yarnton, UK, 2018. [Google Scholar]
- Dolomanov, O.V.; Bourhis, L.J.; Gildea, R.J.; Howard, J.A.K.; Puschmann, H. OLEX2: A complete structure solution refinement and analysis. J. Appl. Cryst. 2009, 42, 339–341. [Google Scholar] [CrossRef]
- Sheldrick, G.M. SHELXT-Integrated Space-Group and Crystal-Structure Determination. Acta Crystallogr. 2015, A71, 3–8. [Google Scholar] [CrossRef]
- Sheldrick, G.M. Crystal Structure Refinement with SHELXL. Acta Crystallogr. 2015, C71, 3–8. [Google Scholar] [CrossRef]
- Mackenzie, C.F.; Spackman, P.R.; Jayatilaka, D.; Spackman, M.A. CrystalExplorer model energies and energy frameworks: Extension to metal coordination compounds, organic salts, solvates and open-shell systems. IUCrJ 2017, 4, 575–587. [Google Scholar] [CrossRef]
- Spackman, P.R.; Turner, M.J.; McKinnon, J.J.; Wolff, S.K.; Grimwood, D.J.; Jayatilaka, D.; Spackman, M.A. CrystalExplorer: A program for Hirshfeld surface analysis, visualization and quantitative analysis of molecular crystals. J. Appl. Crystallogr. 2021, 54, 1006–1011. [Google Scholar] [CrossRef]
- Allen, F.H.; Kennard, O.; Watson, D.G.; Brammer, L.; Orpen, A.G.; Taylor, R. Tables of Bond Lengths determined by X-Ray and Neutron Diffraction. Part 1. Bond Lengths in Organic Compounds. J. Chem. Soc. Perkin Trans. 1987, 2, S1–S19. [Google Scholar] [CrossRef]
- Verma, R.; Jasrotia, D.; Bhat, M. Synthesis and X-ray crystallographic analysis of 17α-hydroxy-17-methylandrost-4-ene-17-one. J. Chem. Crystallogr. 2006, 36, 283–287. [Google Scholar] [CrossRef]
- Angira, D.; Shaik, A.; Kirubakaran, S.; Thiruvenkatam, V. Exploring a solvated dimer of Gefitinib: A quantitative analysis. Acta Crystallogr. C 2018, 74, 944–950. [Google Scholar] [CrossRef] [PubMed]
- Jones, E.C.L.; Goldsmith, K.E.; Ward, M.R.; Bimbo, L.M.; Oswald, I.D.H. Exploring the thermal behaviour of the solvated structures of nifedipine. Acta Crystallogr. B 2023, 79, 164–175. [Google Scholar] [CrossRef] [PubMed]
- Salameh, A.K.; Taylor, L.S. Physical stability of crystal hydrates and their anhydrates in the presence of excipients. J. Pharm. Sci. 2006, 95, 446–461. [Google Scholar] [CrossRef]
- Fujii, K.; Aoki, M.; Uekusa, H. Solid-State Hydration/Dehydration of Erythromycin A Investigated by ab Initio Powder X-ray Diffraction Analysis: Stoichiometric and Nonstoichiometric Dehydrated Hydrate. Cryst. Growth Des. 2013, 13, 2060–2066. [Google Scholar] [CrossRef]
- Dubok, A.S.; Rychkov, D.A. Relative Stability of Pyrazinamide Polymorphs Revisited: A Computational Study of Bending and Brittle Forms Phase Transitions in a Broad Temperature Range. Crystals 2023, 13, 617. [Google Scholar] [CrossRef]










| Crystal | Dbl·0.5H2O | Oxa·0.5H2O | Flu·H2O |
|---|---|---|---|
| Empirical formula | C20H29O2.5 | C19H31O3.5 | C20H31FO4 |
| Formula weight | 309.43 | 315.44 | 354.45 |
| Temperature/K | 293(2) | 293(2) | 293(2) |
| Crystal system | orthorhombic | orthorhombic | orthorhombic |
| Space group | P212121 | P21212 | P212121 |
| a/Å | 6.4730(2) | 22.6998(5) | 7.40120(10) |
| b/Å | 12.6728(4) | 10.3490(3) | 11.6819(2) |
| c/Å | 42.7435(10) | 7.4773(2) | 21.5560(3) |
| α/° | 90 | 90 | 90 |
| β/° | 90 | 90 | 90 |
| γ/° | 90 | 90 | 90 |
| Volume/Å3 | 3506.29(18) | 1756.57(8) | 1863.73(5) |
| Z | 8 | 4 | 4 |
| ρcalcg/cm3 | 1.172 | 1.193 | 1.263 |
| μ/mm−1 | 0.588 | 0.636 | 0.758 |
| F(000) | 1352.0 | 692.0 | 768.0 |
| Radiation | Cu Kα (λ = 1.54184) | Cu Kα (λ = 1.54184) | Cu Kα (λ = 1.54184) |
| 2Θ range for data collection/° | 7.276 to 142.69 | 7.79 to 142.852 | 8.204 to 142.538 |
| Index ranges | −7 ≤ h ≤ 6, −13 ≤ k ≤ 15, −52 ≤ l ≤ 21 | −27 ≤ h ≤ 27, −12 ≤ k ≤ 12, −9 ≤ l ≤ 8 | −9 ≤ h ≤ 9, −14 ≤ k ≤ 11, −26 ≤ l ≤ 26 |
| Reflections collected | 8868 | 24,373 | 26,141 |
| Independent reflections | 5530 [Rint = 0.0220, Rsigma = 0.0347] | 3400 [Rint = 0.0533, Rsigma = 0.0249] | 3570 [Rint = 0.0222, Rsigma = 0.0121] |
| Data/restraints/parameters | 5530/0/417 | 3400/0/211 | 3570/2/234 |
| Goodness-of-fit on F2 | 1.004 | 1.078 | 1.094 |
| Final R indexes [I ≥ 2σ (I)] | R1 = 0.0498, wR2 = 0.1395 | R1 = 0.0424, wR2 = 0.1311 | R1 = 0.0343, wR2 = 0.0926 |
| Final R indexes [all data] | R1 = 0.0616, wR2 = 0.1551 | R1 = 0.0448, wR2 = 0.1356 | R1 = 0.0381, wR2 = 0.0962 |
| Largest diff. peak/hole/e Å−3 | 0.14/−0.30 | 0.19/−0.20 | 0.34/−0.14 |
| Flack parameter | 0.26(17) | −0.04(12) | −0.01(4) |
| Structure | D-H···A | D-H | H···A | D···A | <(D-H···A) |
|---|---|---|---|---|---|
| Dbl·0.5H2O | O2B-H2B···O1A | 0.820 | 2.093 | 2.877(4) | 159.8 |
| O2A-H2A···O1B | 0.820 | 2.106 | 2.907(4) | 165.5 | |
| C2A-H2AA···O1B | 0.930 | 2.667 | 3.561(5) | 161.5 | |
| O3-H3B···O2A | 0.850 | 2.152 | 2.985(5) | 166.4 | |
| C16A-H16B···O3 | 0.970 | 2.678 | 3.433(6) | 135.0 | |
| C6B-H6BA···H20D-C20B | 2.335 | ||||
| O3-H3A···O2B | 0.850 | 2.087 | 2.882(5) | 155.5 | |
| C16B-H16D···O3 | 0.820 | 2.673 | 3.526(7) | 147.0 | |
| C2B-H2BA···O3 | 0.930 | 2.585 | 3.265(6) | 130.4 | |
| C19B-H19E···O1B | 0.960 | 2.695 | 3.381(5) | 128.8 | |
| Oxa·0.5H2O | O2-H2···O1 | 0.820 | 1.978 | 2.789(3) | 170.4 |
| C11-H11A···H18A-C18A | 2.406 | ||||
| O3-H3···O2 | 0.850 | 2.160 | 2.907(2) | 146.2 | |
| C4-H4A···O3 | 0.970 | 2.696 | 3.324(4) | 132.0 | |
| C5-H5···O3 | 0.980 | 2.686 | 3.361(3) | 126.5 | |
| Flu·H2O | O2-H2···O1 | 0. 820 | 2.144 | 2.954(3) | 169.3 |
| C2-H2B···H18A-C18 | 2.327 | ||||
| C15-H15A···F1 | 0.970 | 2.596 | 3.404(3) | 140.9 | |
| C2-H2B···H6B-C6 | 2.372 | ||||
| O3- H3A···O1 | 0.934 | 2.222 | 3.103(3) | 156.9 | |
| O3-H3B···O2 | 0.850 | 2.093 | 2.898(3) | 157.7 |
| Crystal | Eele(kJ/mol) | Epol (kJ/mol) | Edisp (kJ/mol) | Erep (kJ/mol) | Elatt (kJ/mol) |
|---|---|---|---|---|---|
| Dbl·0.5H2O | −29.5 | −7.1 | −48.7 | 26.0 | −59.3 |
| Anhydrous Dbl | −51.0 | −16.5 | −106.9 | 52.4 | −122.0 |
| Flu·H2O | −77.5 | −14.0 | −80.9 | 54.9 | −117.5 |
| Anhydrous Flu | −85.6 | −14.2 | −149.3 | 75.5 | −179.7 |
| Oxa·0.5H2O | −47.3 | −12.5 | −72.4 | 18.8 | −113.4 |
| Anhydrous Oxa | −48.3 | −15.8 | −144.2 | 43.9 | −164.4 |
| Crystal | Interaction Pair | Contact | Eele | Epol | Edisp | Erep | Etot |
|---|---|---|---|---|---|---|---|
| Dbl·0.5H2O | Dbl-Dbl (asym unit) | O2B-H2B···O1A | −39.6 | −7.6 | −10.7 | 21.4 | −36.5 |
| Dbl-Dbl | O2A-H2A···O1B | −35.8 | −7.9 | −13.5 | 21.8 | −35.4 | |
| Dbl-Dbl | C2A-H2AA···O1B | −13.9 | −3.2 | 7.4 | 0 | −24.5 | |
| Dbl-water | O3-H3B···O2A C16A-H16B···O3 | −27.3 | −4.5 | −8.2 | 18.1 | −21.9 | |
| Dbl-Dbl | C6B-H6BA···H20D-C20B | −1.7 | −0.8 | −26.9 | 10.5 | −18.9 | |
| Dbl-water | O3-H3A···O2B C16B-H16D···O3 | −28.0 | −5.5 | −9.5 | 23.0 | −20.0 | |
| Dbl-Dbl | C2B-H2BA···O3 | −4.9 | −1.4 | −5.4 | 5.0 | −6.7 | |
| Dbl-Dbl | C19B-H19E···O1B | −3.6 | −1.8 | −28.5 | 9.5 | −24.4 | |
| Oxa·0.5H2O | Oxa-Oxa | O2-H2···O1 | −42.2 | −9.0 | −11.0 | 0 | −62.2 |
| Oxa-Oxa | C11-H11A···H18A-C18A | −1.0 | −0.9 | −22.8 | 13.2 | −11.5 | |
| Oxa-water | O3-H3···O2 | −5.7 | −2.1 | −6.7 | 5.6 | −8.9 | |
| Oxa-water | C4-H4A···O3 C5-H5···O3 | −5.7 | −2.1 | −6.7 | 5.6 | −8.9 | |
| Flu·H2O | Flu-Flu | O2-H2···O1 | −41.8 | 0 | −14.2 | 23.2 | −32.8 |
| Flu-Flu | C15-H15A···F1 | −6.7 | −0.1 | −35.6 | 11.7 | −30.7 | |
| Flu-Flu | C2-H2A···H18A-C18 | −6.5 | −0.8 | −31.1 | 13.0 | −25.5 | |
| Flu-Water | O4- H4···O3 | −43.5 | −7.8 | −8.2 | 24.6 | −34.9 | |
| Flu-Water | O3-H3B···O2 | −28.2 | −4.3 | −7.9 | 17.7 | −27.7 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Turza, A.; Muresan-Pop, M.; Miclaus, M.O.; Borodi, G. New Solid Forms: Structural, Supramolecular, and Dehydration-Induced Phase Transitions of Three Hydrated 17α-Alkylated Testosterone Derivatives. Crystals 2026, 16, 234. https://doi.org/10.3390/cryst16040234
Turza A, Muresan-Pop M, Miclaus MO, Borodi G. New Solid Forms: Structural, Supramolecular, and Dehydration-Induced Phase Transitions of Three Hydrated 17α-Alkylated Testosterone Derivatives. Crystals. 2026; 16(4):234. https://doi.org/10.3390/cryst16040234
Chicago/Turabian StyleTurza, Alexandru, Marieta Muresan-Pop, Maria O. Miclaus, and Gheorghe Borodi. 2026. "New Solid Forms: Structural, Supramolecular, and Dehydration-Induced Phase Transitions of Three Hydrated 17α-Alkylated Testosterone Derivatives" Crystals 16, no. 4: 234. https://doi.org/10.3390/cryst16040234
APA StyleTurza, A., Muresan-Pop, M., Miclaus, M. O., & Borodi, G. (2026). New Solid Forms: Structural, Supramolecular, and Dehydration-Induced Phase Transitions of Three Hydrated 17α-Alkylated Testosterone Derivatives. Crystals, 16(4), 234. https://doi.org/10.3390/cryst16040234

